

REVANCE®

Revance to Participate in Upcoming Investor Conferences

May 23, 2023

NASHVILLE, Tenn.--(BUSINESS WIRE)--May 23, 2023-- [Revance Therapeutics, Inc.](https://www.businesswire.com/news/home/20230523005850/en/) (RVNC) today announced that the company will be participating in the following investor conferences.

William Blair 43rd Annual Growth Stock Conference

Chief Executive Officer Mark J. Foley is scheduled to participate in a fireside chat on Tuesday, June 6, 2023, at 4:00 P.M. CDT, in Chicago, Illinois.

Goldman Sachs 44th Annual Global Healthcare Conference

Chief Executive Officer Mark J. Foley and President Dustin S. Sjuts are scheduled to participate in a fireside chat on Monday, June 12, 2023, at 8:40 A.M. PDT, in Dana Point, California.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance's aesthetics portfolio of expertly created products and services, including DAXXIFY® (DaxibotulinumtoxinA-ianm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company's elite practice partners and their consumers. Revance has also partnered with Viatrix Inc. to develop a biosimilar to onabotulinumtoxinA for injection, which will compete in the existing short-acting neuromodulator marketplace. Revance's therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY® in two debilitating conditions, cervical dystonia and upper limb spasticity.

Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark, Pleasanton and Irvine, California. Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, or connect with us on [LinkedIn](https://www.linkedin.com/company/revance).

"Revance" and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230523005850/en/): <https://www.businesswire.com/news/home/20230523005850/en/>

Investors

Revance Therapeutics, Inc.:

Jessica Serra, 510-279-6886

jessica.serra@revance.com

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

laurence@gilmartinir.com

Media

Revance Therapeutics, Inc.:

Sara Fahy, 949-887-4476

sfahy@revance.com

Source: Revance Therapeutics, Inc.